Drug intelligence / Profile preview

YW-CARCD19-T

Development stage: Unknown
Lead developer: Vcanbio Cell & Gene Engineering
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

YW-CARCD19-T is an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19. Developed by Vcanbio in collaboration with The Second Hospital of Shanxi Medical University, it is designed for the treatment of patients with relapsed or refractory CD19-positive acute B-lymphoblastic leukemia (B-ALL). The therapy involves genetically modifying a patient's own T cells to express a CAR that specifically binds to CD19 on leukemia cells, leading to targeted cell lysis.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on YW-CARCD19-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YW-CARCD19-T.

Explore the full profile